252 related articles for article (PubMed ID: 30975894)
1. Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and
García-Silva S; Benito-Martín A; Sánchez-Redondo S; Hernández-Barranco A; Ximénez-Embún P; Nogués L; Mazariegos MS; Brinkmann K; Amor López A; Meyer L; Rodríguez C; García-Martín C; Boskovic J; Letón R; Montero C; Robledo M; Santambrogio L; Sue Brady M; Szumera-Ciećkiewicz A; Kalinowska I; Skog J; Noerholm M; Muñoz J; Ortiz-Romero PL; Ruano Y; Rodríguez-Peralto JL; Rutkowski P; Peinado H
J Exp Med; 2019 May; 216(5):1061-1070. PubMed ID: 30975894
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
Broggi MAS; Maillat L; Clement CC; Bordry N; Corthésy P; Auger A; Matter M; Hamelin R; Potin L; Demurtas D; Romano E; Harari A; Speiser DE; Santambrogio L; Swartz MA
J Exp Med; 2019 May; 216(5):1091-1107. PubMed ID: 30975896
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E mutational load as a prognosis biomarker in malignant melanoma.
Sevilla A; Morales MC; Ezkurra PA; Rasero J; Velasco V; Cancho-Galan G; Sánchez-Diez A; Mujika K; Penas C; Smith I; Asumendi A; Cortés JM; Boyano MD; Alonso S
PLoS One; 2020; 15(3):e0230136. PubMed ID: 32168325
[TBL] [Abstract][Full Text] [Related]
5. A Case of Giant Primary Dermal Melanoma with BRAF V600E Mutation.
Imamura T; Nakamura Y; Teramoto Y; Sato S; Asami Y; Arai E; Yamamoto A
Acta Derm Venereol; 2016 Aug; 96(6):840-1. PubMed ID: 26984828
[No Abstract] [Full Text] [Related]
6. Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Hofman V; Ilie M; Long-Mira E; Giacchero D; Butori C; Dadone B; Selva E; Tanga V; Passeron T; Poissonnet G; Emile JF; Lacour JP; Bahadoran P; Hofman P
J Invest Dermatol; 2013 May; 133(5):1378-81. PubMed ID: 23303445
[No Abstract] [Full Text] [Related]
7. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
9. Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
Imrédi E; Tóth B; Doma V; Barbai T; Rásó E; Kenessey I; Tímár J
Melanoma Res; 2016 Jun; 26(3):254-60. PubMed ID: 26848795
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients.
Tas F; Erturk K
Neoplasma; 2019 Jul; 66(4):631-636. PubMed ID: 31058533
[TBL] [Abstract][Full Text] [Related]
12. Progression of NRAS and BRAF mutations in cutaneous melanoma.
Rosso R; Romagosa Y; Kirsner RS
J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
[No Abstract] [Full Text] [Related]
13. Simultaneous BRAF
Wuethrich A; Dey S; Koo KM; Sina AAI; Trau M
Methods Mol Biol; 2021; 2265():265-276. PubMed ID: 33704721
[TBL] [Abstract][Full Text] [Related]
14. Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
Krisp C; Parker R; Pascovici D; Hayward NK; Wilmott JS; Thompson JF; Mann GJ; Long GV; Scolyer RA; Molloy MP
Br J Cancer; 2018 Sep; 119(6):713-723. PubMed ID: 30116025
[TBL] [Abstract][Full Text] [Related]
15. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
16. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF
Schadendorf D; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Lesimple T; Plummer R; Schachter J; Dasgupta K; Manson S; Koruth R; Mookerjee B; Kefford R; Dummer R; Kirkwood JM; Long GV
Lancet Oncol; 2019 May; 20(5):701-710. PubMed ID: 30928620
[TBL] [Abstract][Full Text] [Related]
18. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
19. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
20. Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ.
Vella LJ; Behren A; Coleman B; Greening DW; Hill AF; Cebon J
Neoplasia; 2017 Nov; 19(11):932-940. PubMed ID: 28963969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
